MF101

Summary

Mf101 (CHEMBL3545411) is a phase-3 clinical-stage unknown; indicated across 2 conditions.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545411
Name	MF101
Type	Unknown
Max phase	3

Also known as: Mf101, MF101

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00906308	PHASE3	UNKNOWN	A Study of MF101 in Postmenopausal Women
NCT00119665	PHASE2	COMPLETED	Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes
NCT00454441	PHASE2	COMPLETED	Sleep Quality in CHIMES (MF101)
NCT00453297	PHASE1	TERMINATED	Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components
NCT01300078	PHASE1	UNKNOWN	A Clinical Trial Assessing Safety of MF101 for Hot Flushes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).